행사/교육
Late Phase Drug Development World Americas 2013
- 등록일2013-02-25
- 조회수3822
- 구분 국외
- 행사교육분류 행사
-
주관기관
Health Network Communications Ltd
-
행사장소
Hyatt Regency Boston - Boston
-
행사기간
2013-03-20 ~ 2013-03-21
- 원문링크
- 첨부파일
brochure.pdf
Late Phase Drug Development World Americas 2013
Conference programme
Day One- Wednesday 20th March
Conference
8am Registration
8.50am Opening remarks from the chair
9am Critical aspects of late phase development
Building a comprehensive clinical profile of therapeutics in the real world
9.30am Collecting data on real-life clinical practice regarding safety and efficacy in rare genetic disease
› Alaa Hamed, MD, MPH, MBA, Head, Genzyme Evidence & Value Development, Genzyme CorporationCollecting data on real-life clinical practice regarding safety and efficacy in rare genetic disease
10am Propensity scores: Are they a panacea for comparative effectiveness?
10.30am How to integrate planning and execution of Phase IV clinical trials under medical affairs rather than clinical development
› Jeffrey Stoddard, VP and Global Head, Medical Affairs, Novartis
How to integrate planning and execution of Phase IV clinical trials under medical affairs rather than clinical development
11am Morning refreshments and speed networking
11.50am Strategic evidence generation over the late phase product life-cycle: optimizing cost & timeline effectiveness
› Krista Payne, Executive Director and Senior Research Scientist, Peri- and Post-Approval Services, United Biosource Corporation
Strategic evidence generation over the late phase product life-cycle: optimizing cost & timeline effectiveness
The role of comparative effectiveness in late phase studies
12pm Challenges in drug comparative effectiveness studies
› Omar Dabbous, Senior Director, Head of Global Health Economics and Outcomes Research, Takeda Challenges in drug comparative effectiveness studies
12.45pm Best practice in head-to-head clinical comparative trials of clinically relevant treatment alternatives
› Glen Frick, Medical Director, Shire
Best practice in head-to-head clinical comparative trials of clinically relevant treatment alternatives
1.10pm Novel approaches to evaluating clinical effectiveness and patient-centered information
› Jill Abell, Senior Director, Clinical Effectiveness, GSK
Novel approaches to evaluating clinical effectiveness and patient-centered information
1.35pm Lunch
1330 Lunch Evidence and value development for payers
2.30pm Observational Research: Areas of Consensus and Divergence
› Jeffrey Trotter, Executive VP, Phase IV Development, inVentiv Health Clinical
Observational Research: Areas of Consensus and Divergence
3pm The value of prospective observational studies in enhacing our understanding of patients' needs and informing health care decision making
› Mary Panaccio, Senior Director, Evidence Based Medicine, US Medical Affairs, Sanofi
The value of prospective observational studies in enhacing our understanding of patients' needs and informing health care decision making
3.30pm Afternoon refreshments
4pm Driving value in post approval studies
› Teresa Simon, Director Global Health Economics and Outcomes Research, BMS
Driving value in post approval studies
4.30pm Case study: Addressing multiple stakeholder demands for real world value and efficacy
› Wenhui Wei, Director, Evidence Based Medicine, Sanofi
Case study: Addressing multiple stakeholder demands for real world value and efficacy
5pm Closing remarks from the chair and end of day one
5.15pm Networking drinks reception
........(계속)
☞ 자세한 내용은 내용바로가기를 이용하시기 바랍니다.